XERS

Xeris Biopharma Holdings Inc

Add to Watchlist

Advanced Chart

7.360

+0.16(2.222%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.470

Open

7.3093

VWAP

7.33

Vol

1.23M

Mkt Cap

1.16B

Low

7.190

Amount

9.03M

EV/EBITDA(TTM)

482.13

Total Shares

148.26M

1.32B

EV/OCF(TTM)

P/S(TTM)

4.46

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

73.45M

+35.35%

77.95M

+29.7%

78.73M

+30.96%

Estimates Revision

The market is revising Upward the revenue expectations for Xeris Biopharma Holdings, Inc. (XERS) for FY2025, with the revenue forecasts being adjusted by 1.01% over the past three months. During the same period, the stock price has changed by 48.69%.

Revenue Estimates for FY2025

Revise Upward

+1.01%

In Past 3 Month

Stock Price

Go Up

+48.69%

In Past 3 Month

5 Analyst Rating

-20.11% Downside

Wall Street analysts forecast XERS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 5.88 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

-20.11% Downside

Current: 7.360

Low

4.00

Averages

5.88

High

7.00

-20.11% Downside

Current: 7.360

Low

4.00

Averages

5.88

High

7.00

Oppenheimer

Outperform

maintain

$7 -> $8

2025-08-08

New

Reason

Oppenheimer

Price Target

$7 -> $8

2025-08-08

New

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Xeris Biopharma to $8 from $7 and keeps an Outperform rating on the shares following quarterly results. The firm cites outlook for continued commercial execution and sustainable growth.

Oppenheimer

Outperform

maintain

$6 -> $7

2025-05-09

Reason

Oppenheimer

Price Target

$6 -> $7

2025-05-09

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Xeris Biopharma to $7 from $6 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 total revenue of $60.1M, which topped OpCo/consensus estimates on solid Recorlev/Gvoke performance and Keveyis durability. Management tightened full-year guidance to $260M-$275M from $255M-$275M, and the firm expects adjusted EBITDA to be consistently positive going forward. No apparent tariff threat as manufacturing is wholly domestic. Oppenheimer looks forward to the June 3 analyst day at which a key focus will be the company's subcutaneous levothyroxine for hypothyroidism.

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$5 → $6.5

2025-03-07

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$5 → $6.5

2025-03-07

Maintains

Strong Buy

Reason

Leerink Partners

Roanna Ruiz

Buy

Maintains

$5 → $6

2025-03-07

Reason

Leerink Partners

Roanna Ruiz

Price Target

$5 → $6

2025-03-07

Maintains

Buy

Reason

HC Wainwright & Co.

Oren Livnat

Strong Buy

Reiterates

$6.6 → $8

2025-03-07

Reason

HC Wainwright & Co.

Oren Livnat

Price Target

$6.6 → $8

2025-03-07

Reiterates

Strong Buy

Reason

Piper Sandler

David Amsellem

Hold

Reiterates

$3 → $4

2025-03-07

Reason

Piper Sandler

David Amsellem

Price Target

$3 → $4

2025-03-07

Reiterates

Hold

Reason

Piper Sandler raised the firm's price target on Xeris Biopharma to $4 from $3 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q4 net loss per share of (3c) on total revenues of $60.1M, compared to Street estimates of (6c) and $58.1M, respectively. Management is guiding to 2025 total revenue of $255M-$275M, implying annual growth of about 35% versus 2024 at the midpoint.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Xeris Biopharma Holdings Inc (XERS.O) is 53.03, compared to its 5-year average forward P/E of -13.13. For a more detailed relative valuation and DCF analysis to assess Xeris Biopharma Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.13

Current PE

53.03

Overvalued PE

74.18

Undervalued PE

-100.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-17.95

Current EV/EBITDA

25.05

Overvalued EV/EBITDA

96.62

Undervalued EV/EBITDA

-132.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

2.01

Current PS

3.50

Overvalued PS

2.60

Undervalued PS

1.41